Englander Institute for Precision Medicine
Found 869 results
Author Title Type [ Year(Asc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2022
Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E.  2022.  A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients.. Oncoimmunology. 11(1):2059878.
Summers BD, Kim K, Clement CC, Khan Z, Thangaswamy S, McCright J, Maisel K, Zamora S, Quintero S, Racanelli AC et al..  2022.  Lung lymphatic thrombosis and dysfunction caused by cigarette smoke exposure precedes emphysema in mice.. Sci Rep. 12(1):5012.
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):115-141.
Chetnik K, Benedetti E, Gomari DP, Schweickart A, Batra R, Buyukozkan M, Wang Z, Arnold M, Zierer J, Suhre K et al..  2022.  maplet: an extensible R toolbox for modular and reproducible metabolomics pipelines.. Bioinformatics. 38(4):1168-1170.
Tombal B, Sternberg CN, Hussain M, Ganguli A, Li Y, Sandin R, Bhadauria H, Oh M, Saad F.  2022.  Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.. ESMO Open. 7(3):100510.
Jiménez-Cortegana C, Galassi C, Galluzzi L.  2022.  MDSCs sneak CSCs out of (immuno)surveillance.. Trends Immunol. 43(1):1-3.
Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, Moore MD, Ullmann TM, Thiesmeyer JW, Loewenstein Z et al..  2022.  Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.. JCI Insight. 7(23)
Ferrara CR, Bai JDong K, McNally EM, Putzel GG, Zhou XKathy, Wang H, Lang A, Nagle D, Denoya P, Krumsiek J et al..  2022.  Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis, and the Metabolome.. Cancer Prev Res (Phila). 15(12):803-814.
Ganly I, Liu EMinwei, Kuo F, Makarov V, Dong Y, Park J, Gong Y, Gorelick AN, Knauf JA, Benedetti E et al..  2022.  Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma.. Sci Adv. 8(25):eabn9699.
Ruthig VA, Lamb DJ.  2022.  Modeling development of genitourinary birth defects to understand disruption due to changes in gene dosage.. Am J Clin Exp Urol. 10(6):412-424.
Martinez-Fundichely A, Dixon A, Khurana E.  2022.  Modeling tissue-specific breakpoint proximity of structural variations from whole-genomes to identify cancer drivers.. Nat Commun. 13(1):5640.
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G et al..  2022.  Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.. Eur Urol. 82(3):261-270.
Santambrogio L.  2022.  Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.. Front Immunol. 13:878271.
Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, Gaffney CD, Shoag J, Tu JJenny, Khani F et al..  2022.  A multidisciplinary approach to optimize primary prostate cancer biobanking.. Urol Oncol. 40(6):271.e1-271.e7.
Klapp V, Galluzzi L.  2022.  Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.. Trends Cancer. 8(1):1-3.
Batra R, Whalen W, Alvarez-Mulett S, Gómez-Escobar LG, Hoffman KL, Simmons W, Harrington J, Chetnik K, Buyukozkan M, Benedetti E et al..  2022.  Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. medRxiv.
Batra R, Whalen W, Alvarez-Mulett S, Gómez-Escobar LG, Hoffman KL, Simmons W, Harrington J, Chetnik K, Buyukozkan M, Benedetti E et al..  2022.  Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. PLoS Pathog. 18(9):e1010819.
Jiménez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, Galluzzi L.  2022.  Myeloid-Derived Suppressor Cells and Radiotherapy.. Cancer Immunol Res. 10(5):545-557.
Podaza E, Kuo H-H, Nguyen J, Elemento O, M Martin L.  2022.  Next generation patient derived tumor organoids.. Transl Res. 250:84-97.
Hu Y, Bloy N, Elemento O, Buqué A.  2022.  Nicotinamide drives T cell activation in the mammary tumor microenvironment.. J Transl Med. 20(1):251.
Tong L, Jiménez-Cortegana C, Tay AHM, Wickström S, Galluzzi L, Lundqvist A.  2022.  NK cells and solid tumors: therapeutic potential and persisting obstacles.. Mol Cancer. 21(1):206.
Drozdz MM, Doane AS, Alkallas R, Desman G, Bareja R, Reilly M, Bang J, Yusupova M, You J, Eraslan Z et al..  2022.  A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation.. Cell Rep. 40(13):111412.
Lorenzin F, Demichelis F.  2022.  Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.. Cancers (Basel). 14(5)
Clement CC, Osan J, Buqué A, Nanaware PP, Chang Y-C, Perino G, Shetty M, Yamazaki T, Tsai WLi, Urbanska AM et al..  2022.  PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.. Sci Immunol. 7(74):eabl3795.
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.